Ferric maltol | CAS#33725-54-1 | oral iron supplement

MedKoo Cat#: 330228 | Name: Ferric maltol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ferric maltoll, sold under the brand names Accrufer and Feraccru, is for the treatment of adults with low iron stores. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Ferric maltol can cause serious side effects including increased risk of inflammatory bowel disease flare and iron overload in the body.

Chemical Structure

Ferric maltol

CAS#33725-54-1

Theoretical Analysis

MedKoo Cat#: 330228

Name: Ferric maltol

CAS#: 33725-54-1

Chemical Formula: C18H15FeO9

Exact Mass: 0.0000

Molecular Weight: 431.15

Elemental Analysis: C, 50.14; H, 3.51; Fe, 12.95; O, 33.40

Price and Availability

Size	Price	Availability
250mg	USD 250.00	2 Weeks
500mg	USD 400.00	2 Weeks
1g	USD 700.00	2 Weeks
2g	USD 1,250.00	2 Weeks
5g	USD 2,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Ferric maltol; Iron (III) maltol; ST10; ST-10; ST 10; ST10-021; ST-10-021; ST 10-021; ST10021; ST-10021; ST 10021; WHO 9974; WHO-9974; WHO9974;

IUPAC/Chemical Name

iron(III) 2-methyl-4-oxo-4H-pyran-3-olate

InChi Key

AHPWLYJHTFAWKI-UHFFFAOYSA-K

InChi Code

InChI=1S/3C6H6O3.Fe/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3

SMILES Code

CC(OC=C1)=C2C1=[O+][Fe]34([O+]=C5C([O-]3)=C(C)OC=C5)([O-]C6=C(C)OC=CC6=[O+]4)[O-]2

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 431.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Khoury A, Pagan KA, Farland MZ. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults. Ann Pharmacother. 2021 Feb;55(2):222-229. doi: 10.1177/1060028020941014. Epub 2020 Jul 7. PMID: 32633548. 2: Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis. 2022 Jun;79(6):868-876. doi: 10.1053/j.ajkd.2021.09.017. Epub 2021 Nov 7. PMID: 34758368. 3: Schmidt C, Allen S, Kopyt N, Pergola P. Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion. J Clin Med. 2021 Sep 28;10(19):4448. doi: 10.3390/jcm10194448. PMID: 34640466; PMCID: PMC8509126. 4: Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859-67. doi: 10.1517/14656566.2015.1096929. Epub 2015 Nov 23. PMID: 26595432. 5: Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis. 2021 Dec;78(6):846-856.e1. doi: 10.1053/j.ajkd.2021.03.020. Epub 2021 May 23. PMID: 34029682. 6: Howaldt S, Domènech E, Martinez N, Schmidt C, Bokemeyer B. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial. Inflamm Bowel Dis. 2022 Mar 2;28(3):373-384. doi: 10.1093/ibd/izab073. Erratum in: Inflamm Bowel Dis. 2021 Oct 06;: PMID: 33988236; PMCID: PMC8889281. 7: Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A; AEGIS Study Group. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015 Mar;21(3):579-88. doi: 10.1097/MIB.0000000000000314. PMID: 25545376; PMCID: PMC4342319. 8: Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. doi: 10.1111/apt.13665. Epub 2016 May 29. PMID: 27237709; PMCID: PMC5089582. 9: Farrell D, Artom M, Czuber-Dochan W, Jelsness-Jørgensen LP, Norton C, Savage E. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD012005. doi: 10.1002/14651858.CD012005.pub2. PMID: 32297974; PMCID: PMC7161727. 10: Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, Engineer J, Akobeng AK. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev. 2021 Jan 20;1(1):CD013529. doi: 10.1002/14651858.CD013529.pub2. PMID: 33471939; PMCID: PMC8092475. 11: Mahalhal A, Frau A, Burkitt MD, Ijaz UZ, Lamb CA, Mansfield JC, Lewis S, Pritchard DM, Probert CS. Oral Ferric Maltol Does Not Adversely Affect the Intestinal Microbiome of Patients or Mice, But Ferrous Sulphate Does. Nutrients. 2021 Jun 30;13(7):2269. doi: 10.3390/nu13072269. PMID: 34209042; PMCID: PMC8308237. 12: Olsson KM, Fuge J, Brod T, Kamp JC, Schmitto J, Kempf T, Bauersachs J, Hoeper MM. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. Eur Respir J. 2020 Nov 12;56(5):2000616. doi: 10.1183/13993003.00616-2020. PMID: 32444411; PMCID: PMC7676873. 13: Cummings JF, Fraser A, Stansfield C, Beales I, Sebastian S, Hoque S. Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK. BMJ Open Gastroenterol. 2021 Feb;8(1):e000530. doi: 10.1136/bmjgast-2020-000530. PMID: 33622683; PMCID: PMC7907848. 14: Allen S, Auth MK, Kim JJ, Vadamalayan B. Safety, Tolerability, and Pharmacokinetics of Oral Ferric Maltol in Children With Iron Deficiency: Phase 1 Study. JPGN Rep. 2021 Jun 15;2(3):e090. doi: 10.1097/PG9.0000000000000090. PMID: 37205968; PMCID: PMC10191551. 15: Barrand MA, Callingham BA, Dobbin P, Hider RC. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol. 1991 Mar;102(3):723-9. doi: 10.1111/j.1476-5381.1991.tb12240.x. PMID: 1364845; PMCID: PMC1917947. 16: Howaldt S, Domènech E, Martinez N, Schmidt C, Bokemeyer B. Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial. Inflamm Bowel Dis. 2022 Mar 2;28(3):494. doi: 10.1093/ibd/izab224. Erratum for: Inflamm Bowel Dis. 2022 Mar 2;28(3):373-384. PMID: 34612489; PMCID: PMC8889305. 17: Barrand MA, Hider RC, Callingham BA. The importance of reductive mechanisms for intestinal uptake of iron from ferric maltol and ferric nitrilotriacetic acid (NTA). J Pharm Pharmacol. 1990 Apr;42(4):279-82. doi: 10.1111/j.2042-7158.1990.tb05408.x. PMID: 1974298. 18: Kelsey SM, Hider RC, Bloor JR, Blake DR, Gutteridge CN, Newland AC. Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test. J Clin Pharm Ther. 1991 Apr;16(2):117-22. doi: 10.1111/j.1365-2710.1991.tb00292.x. PMID: 1856249. 19: Kelsey SM, Blake DR, Hider RC, Gutteridge CN, Newland AC. Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects. Clin Lab Haematol. 1989;11(3):287-8. doi: 10.1111/j.1365-2257.1989.tb00222.x. PMID: 2591161. 20: Bokemeyer B, Krummenerl A, Maaser C, Howaldt S, Mroß M, Mallard N. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency. Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):229-238. doi: 10.1007/s13318-016-0334-5. PMID: 27101422.

View History

Alvimopan Dihydrate